New Product
Pasthil.
Pasthil is a line of herbal lozenges (pastilles) produced by Leda Pharma (Leda İlaç), a pharmaceutical company based in Turkey. These products are primarily used to soothe throat irritation, relieve coughs, and support the immune system. They are generally classified as food supplements rather than prescription medications. Here are the key details about Pasthil products: 1. Common Ingredients Depending on the specific variety, Pasthil lozenges typically contain a combination of: Propolis: Known for its natural antibacterial and antiviral properties. Ginger & Turmeric: Used for their anti-inflammatory effects. Vitamin C: To support the immune system. Menthol/Peppermint: To provide a cooling sensation and open the airways. Honey & Lemon: To coat and soothe a dry or scratchy throat. 2. Popular Variants Leda Pharma usually offers several "flavors" or formulations, such as: Pasthil Ginger & Lemon: Focuses on refreshing the throat and reducing nausea or irritation. Pasthil Propolis: Aimed at stronger immune support and treating more painful throat conditions. Pasthil Orange: Often packed with extra Vitamin C. 3. What is it used for? Sore Throat: Relieving pain and scratchiness. Hoarseness: Helping to clear the voice. Cough Relief: Suppressing the urge to cough by keeping the throat moist. Mouth Hygiene: Refreshing the breath and providing mild antiseptic benefits. 4. How to Use Dosage: Usually, it is recommended to dissolve one lozenge slowly in the mouth every 2–3 hours. Caution: Because they often contain sugar or sweeteners, people with diabetes should check the specific packaging. They are generally not recommended for very young children due to the risk of choking.
Decomit® (Beclomethasone Dipropionate) 50mg Nasal Spray BP (100ml)
Indications of Decomit Nasal Spray
Beclometasone 50, 100 & 250 HFA Inhaler is shown within the prophylactic administration of mellow, direct, or extreme asthma in grown-ups or children. Beclometasone dipropionate given by inward breath offers preventative treatment for asthma. It provides effective anti-inflammatory activity within the lungs with a lower rate and seriousness of antagonistic impacts than those watched when corticosteroids are managed systemically. Mild asthma: Patients requiring symptomatic bronchodilator asthma medicine on a normal basis. Moderate asthma: Patients with unsteady or declining asthma in spite of prophylactic treatment or bronchodilator alone. Severe asthma: Patients with extreme incessant asthma and those who are subordinate on systemic corticosteroids for satisfactory control of indications. Numerous patients who are subordinate on systemic corticosteroids for satisfactory control of indications may be able to decrease altogether, or kill, their prerequisite for verbal corticosteroids when they are exchanged to tall measurements